IL2 and neoplasm: To further evaluate the effect of the IL-15:IL-15Rα-B16F10-OVA vaccine on tumor-specific cytotoxic T cell activity, C57BL/6J mice (n = 5) were vaccinated as shown in Figure 3A. The splenocytes derived from tumor-bearing mice then underwent antigenic stimulation with treatment with an OVA peptide in the presence of IL-2 for 72 h in vitro.